References
- Peters JC. Tryptophan nutrition and metabolism: an overview. Adv Exp Med Biol 1991;294:345-58
- Hayaishi O. My life with tryptophan–never a dull moment. Protein Sci 1993;2:472-5
- Lapin IP, Oxenkrug GF. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet 1969;1:132-6
- Raison CL, Dantzer R, Kelley KW, et al. CSF Concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-: Relationship to CNS immune responses and depression. Mol Psychiatry 2010;15:393-403
- Raison CL, Miller AH. Do cytokines really sing the blues? Cerebrum 2013;2013:10
- Colabroy KL, Begley TP. Tryptophan catabolism: identification and characterization of a new degradative pathway. J Bacteriol 2005;187:7866-9
- Geng J, Liu A. Heme-dependent dioxygenases in tryptophan oxidation. Arch Biochem Biophys 2014;544:18-26
- Mandi Y, Vecsei L. The kynurenine system and immunoregulation. J Neural Transm 2012;119:197-209
- Schwarcz R, Bruno JP, Muchowski PJ, et al. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 2012;13:465-77
- Fetzner S. Ring-cleaving dioxygenases with a cupin fold. Appl Environ Microbiol 2012;78:2505-14
- Stone TW, Darlington LG. Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov 2002;1:609-20
- Stone TW, Stoy N, Darlington LG. An expanding range of targets for kynurenine metabolites of tryptophan. Trends Pharmacol Sci 2013;34:136-43
- Miller AH. Conceptual confluence: The kynurenine pathway as a common target for ketamine and the convergence of the inflammation and glutamate hypotheses of depression. Neuropsychopharmacology 2013;38:1607-8
- Schwarcz R. The kynurenine pathway of tryptophan degradation as a drug target. Curr Opin Pharmacol 2004;4:12-17
- Stone TW, Mackay GM, Forrest CM, et al. Tryptophan metabolites and brain disorders. Clin Chem Lab Med 2003;41:852-9
- Irwin MR, Miller AH. Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun 2007;21:374-83
- Beal MF, Matson WR, Swartz KJ, et al. Kynurenine pathway measurements in Huntington’s disease striatum: evidence for reduced formation of kynurenic acid. J Neurochem 1990;55(4):1327-39
- Perez-De La Cruz V, Carrillo-Mora P, Santamaria A. Quinolinic acid, an endogenous molecule combining excitotoxicity, oxidative stress and other toxic mechanisms. Int J Tryptophan Res 2012;5:1-8
- Huo L, Davis I, Chen L, et al. The power of two: arginine 51 and arginine 239* from a neighboring subunit are essential for catalysis in α-amino-β-carboxymuconate-ϵ-semialdehyde decarboxylase. J Biol Chem 2013;288:30862-71
- Huo L, Liu F, Iwaki H, et al. Human α-amino-β-carboxymuconate-ϵ-semialdehyde decarboxylase (ACMSD): a structural and mechanistic unveiling. Proteins 2015;83:178-87
- Grant RS, Coggan SE, Smythe GA. The physiological action of picolinic acid in the human brain. Int J Tryptophan Res 2009;2:71-9
- Huo L, Davis I, Liu F, et al. Crystallographic and spectroscopic snapshots reveal a dehydrogenase in action. Nat Commun 2015;6:5935
- Zhang Y, Colabroy KL, Begley TP, et al. Structural studies on 3-hydroxyanthranilate-3,4-dioxygenase: the catalytic mechanism of a complex oxidation involved in NAD biosynthesis. Biochemistry 2005;44:7632-43
- Crunkhorn S. Deal watch: Genentech dives deeper into the next wave of cancer immunotherapies. Nat Rev Drug Discov 2014;13:879